Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc.

Analysts are intrested in these 5 stocks: ( ($REGN) ), ( ($CRCL) ), ( ($BURL) ), ( ($ROST) ) and ( ($PBA) ). Here is a breakdown of their recent


Regeneron, Circle, Burlington, Ross, Pembina Trending With Analysts

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN) and Merck & Company (MRK) with bull...

Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Merck & Company (MRK)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals has completed a mid-stage clinical...

Regeneron’s REGN7544 Trial Reaches Key Milestone in Sepsis-Induced Hypotension

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin Pharmaceutical (BMRN) and Regeneron (REGN...

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Regeneron (REGN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Veracyte (VCYT), Tonix Pharma (TNXP) and Regeneron...

Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Tonix Pharma (TNXP) and Regeneron (REGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN) and Korro Bio (KRRO) with bullish s...

Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Korro Bio (KRRO)

Citi analyst Geoff Meacham downgraded Regeneron to a Hold yesterday and set a price target of $700.00. According to TipRanks, Meacham is a 5-star a...

Citi downgrades Regeneron (REGN) to a Hold

Last week, stocks pulled back from record highs as oil, yields, and rate fears returned to the forefront. The S&P 500 (SPX) ended at 7,408.50, down...

The Week That Was, The Week Ahead: Macro and Markets, May 17

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The study, called “A Prospective, Observati...

Real-World Dupixent Data in Canada: What Regeneron and Sanofi Investors Should Watch

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Geron (GERN), Regeneron (REGN) and TScan Therapeutic...

Analysts Are Bullish on These Healthcare Stocks: Geron (GERN), Regeneron (REGN)

BMO Capital analyst Evan Seigerman maintained a Buy rating on Regeneron today and set a price target of $900.00. Seigerman covers the Healthcare se...

Regeneron (REGN) Receives a Buy from BMO Capital

Citi analyst Geoff Meacham maintained a Buy rating on Regeneron today and set a price target of $900.00. According to TipRanks, Meacham is a 5-star...

Citi Reaffirms Their Buy Rating on Regeneron (REGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN), Bausch + Lomb Corporation (BLCO) and Indivior (...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Bausch + Lomb Corporation (BLCO) and Indivior (INDV)

Here’s a quick look at today’s key earnings reports from major publicly traded companies. Investors will be watching closely for updates on financi...

Current Quarter	$8.4	Next Quarter	$10.54
Current Year	$37.1	Next Year	$41.51
QoQ Growth	+25.5%	YoY Growth	+11.9%
3Y EPS CAGR	+2.1%	Target Price	$876.54
Consensus	Buy	Upside	+37.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REGN	$638.88	-0.58%	995.02K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REGN	$638.88	-0.6%	995.02K
3
4
5
6

REGN

REGN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Regeneron Pharmaceuticals Inc. Data in Excel

Get Regeneron Pharmaceuticals Inc. Data in Excel